TW320562B - - Google Patents

Download PDF

Info

Publication number
TW320562B
TW320562B TW83110090A TW83110090A TW320562B TW 320562 B TW320562 B TW 320562B TW 83110090 A TW83110090 A TW 83110090A TW 83110090 A TW83110090 A TW 83110090A TW 320562 B TW320562 B TW 320562B
Authority
TW
Taiwan
Prior art keywords
day
compound
economic affairs
cns
ministry
Prior art date
Application number
TW83110090A
Other languages
English (en)
Chinese (zh)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of TW320562B publication Critical patent/TW320562B/zh

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW83110090A 1993-07-19 1994-11-02 TW320562B (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27746093A 1993-07-19 1993-07-19
US26085794A 1994-06-16 1994-06-16

Publications (1)

Publication Number Publication Date
TW320562B true TW320562B (ja) 1997-11-21

Family

ID=51567009

Family Applications (1)

Application Number Title Priority Date Filing Date
TW83110090A TW320562B (ja) 1993-07-19 1994-11-02

Country Status (1)

Country Link
TW (1) TW320562B (ja)

Similar Documents

Publication Publication Date Title
US5538992A (en) Potentiation of drug response
US6169105B1 (en) Potentiation of drug response
JP5431136B2 (ja) 薬剤を製造するためのミルナシプランの（１ｓ，２ｒ）エナンチオマーの使用
US20030130355A1 (en) Therapeutic agents
JP2001503737A (ja) 糖尿病の発生を防止するためのシブトラミン類似体の利用
JP2002501892A (ja) 光学的に純粋な（−）−ビュープロピオンの薬学的使用
EP0759299B1 (en) Potentiation of serotonin response
CN103189358A (zh) 5-ht2c激动剂的快速溶解剂型
CA2138998A1 (en) Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
US5958429A (en) Potentiation of serotonin response
CA2139000A1 (en) Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine
EP0792649A1 (en) Treatment of sleep disorders
JP2002501890A (ja) 光学的に純粋な（＋）−ビュープロピオンの薬学的使用
TW320562B (ja)
SK13382001A3 (sk) Použitie zlúčeniny a farmaceutická kompozícia ju obsahujúca
CA2123704C (en) Methods and compositions utilizing pure s(+)isomer fluoxetine
CN105163729A (zh) 用于治疗与帕金森氏病相关的运动和抑郁症状的方法、组合物和装置
US6552087B1 (en) Therapeutic agent comprising (+)-sibutramine
TW200539859A (en) Methods for increasing neurotransmitter levels using hydroxycitric acid
US20230024207A1 (en) Method and a dietary composition on regulation, treatment, and prevention of obesity
EP0818198A1 (en) Potentiation of drug response by increasing serotonin availability
WO1992013452A1 (en) Methods of use and compositions of r(-) fluoxetine
JP2002539250A (ja) 肺高血圧症の治療
US20060122261A1 (en) [method of preparing labdane diterpene composition, preferably isoforskolin and deacetylforskolin from forskolin extract and their use for promoting lean body mass and other applications]
JP2002539252A (ja) 胆石の治療